‘Time to Strike,' Says Investor About Nvidia Stock
Nvidia (NASDAQ:NVDA) has faced a challenging landscape in 2025, navigating a mix of uncertainties. Export restrictions have complicated its business in China, and broader concerns about the pace of capex investments by hyperscalers have added a layer of caution to the growth narrative that once seemed unstoppable.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Still, not everyone is hitting the panic button. Despite a nearly 15% year-to-date slide, investor Bohdan Kucheriavyi argues that the risks are overblown – and there are blue skies aplenty for Nvidia up ahead.
'I'm still confident in the company's ability to create additional shareholder value over the following years,' asserts the 5-star investor.
That's not to say that Kucheriavyi is dismissive of the very real risks of decreasing capex spending by the hyperscalers – far from it. The investor notes the recent reports that Microsoft and Amazon have been walking away from data center leases, a move that could signal cooling demand for Nvidia's chips. But in the same breath, he highlights evidence pointing in the opposite direction: AI spending among hyperscalers is still on track to hit $300 billion this year. Strong results from TSMC and even AI momentum at beleaguered Intel hint that the appetite for AI infrastructure isn't fading.
Meanwhile, Nvidia is actively adapting to geopolitical headwinds. The company is shifting key production of its next-gen Blackwell chips to TSMC's Arizona facility. By localizing production, Nvidia aims to mitigate risks associated with geopolitical tensions, such as potential tariffs and export restrictions, and to better meet the growing demand for AI chips and supercomputers.
'This should help the company be less exposed to any geopolitical and tariff-related risks, which is a major upside in the current environment,' adds Kucheriavyi.
The investor also acknowledges the added difficulties the company will face in the Chinese market in the years ahead, as trade restrictions will give domestic competitors such as Huawei a pronounced leg up over the American firm.
Even so, a 10% sales hit tied to China-related disruptions hasn't shaken his conviction. In his view, Nvidia remains undervalued – and the long-term upside is still very much intact.
'Nvidia's upside remains significant, even if we take into account the loss of China-related revenues this year,' concludes Kucheriavyi, who rates NVDA stock a Buy. (To watch Kucheriavyi's track record, click here)
Wall Street needs no additional convincing. With 34 Buys, 5 Holds and a single Sell, NVDA enjoys a Strong Buy consensus rating. Its 12-month average price target of $164.23 implies a ~43% upside for the year ahead. (See NVDA stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
eXp Realty Dominates 2025 RealTrends Rankings With 757 Agents and Teams Honored
40 eXp Realty agents and teams break into the elite 'The Thousand' list, and the firm claims #1 spot for transactions nationwideBELLINGHAM, Wash., June 10, 2025 (GLOBE NEWSWIRE) -- eXp Realty®, 'the most agent-centric real estate brokerage on the planet™' and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced that a record-breaking 757 of its agents and teams have been named among the top real estate professionals in the country, according to the 2025 RealTrends Verified America's Best List. With fewer than 0.1% of agents qualifying nationwide, inclusion in the RealTrends rankings is a rare achievement that reflects exceptional production and service. Adding to the celebration, eXp Realty also ranked as the: #1 Brokerage in the U.S. by Transaction Sides #3 Brokerage in the U.S. by Sales Volume These accolades underscore eXp's continued dominance in the real estate space and its commitment to supporting agents through a robust cloud-based platform, best-in-class tools, and unparalleled collaboration opportunities. 'At eXp Realty, our agents are our greatest asset. Seeing 757 of our professionals earn recognition on the RealTrends lists is both humbling and energizing,' said Leo Pareja, CEO of eXp Realty. 'This success is a direct result of our commitment to providing agents with the tools, model, and culture they need to thrive. We are building something extraordinary, and this achievement is a powerful testament to the strength of our community.' With a mission to empower agents to build better businesses, eXp Realty continues to redefine what's possible in real estate, offering top-tier financial incentives, cutting-edge technology, and a globally connected network – all of which contribute to driving results for clients and professionals alike. About eXp World Holdings, Inc. eXp World Holdings, Inc. (Nasdaq: EXPI) (the 'Company') is the holding company for eXp Realty® and SUCCESS® Enterprises. eXp Realty is the largest independent real estate brokerage in the world, with over 81,000 agents across 27 countries. As a cloud-based, agent-centric brokerage, eXp Realty provides real estate agents industry-leading commission splits, revenue share, equity ownership opportunities, and a global network that empowers agents to build thriving businesses. For more information about eXp World Holdings, Inc., visit: SUCCESS® Enterprises, anchored by SUCCESS® magazine, has been a trusted name in personal and professional development since 1897. As part of the eXp ecosystem, it offers agents access to valuable resources to enhance their skills, grow their businesses, and achieve long-term success. For more information about SUCCESS, visit Safe Harbor and Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's and its management's current expectations but involve known and unknown risks and uncertainties that could impact actual results materially. These statements include, but are not limited to, statements regarding the anticipated success of agents or teams joining eXp Realty, future production goals or volume projections, and participation in or benefits derived from the Company's platform, tools, compensation model, or equity programs. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include real estate market fluctuations, changes in agent retention or recruitment, the Company's ability to expand successfully in international markets, competitive pressures, regulatory changes, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings, including but not limited to the most recently filed Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. We do not undertake any obligation to update these statements except as required by law. Media Relations Contact:eXp World Holdings, Investor Relations Contact:Denise Garciainvestors@ A photo accompanying this announcement is available at
Yahoo
9 minutes ago
- Yahoo
New IBO Survey Reveals Major Cuts to Lab Budgets Amid NIH Grant Terminations
ARLINGTON, Va., June 10, 2025 /PRNewswire/ -- A new survey conducted by Instrument Business Outlook (IBO) has uncovered significant reductions in laboratory budgets across the U.S. academic and government research landscape, with lab product spending sharply impacted by recent NIH grant terminations. The findings, based on an exclusive IBO survey, shed light on the growing financial uncertainty facing scientific research labs in 2025. The results follow widespread disruptions in NIH funding, with more than 1,500 grants totaling $7.5 billion terminated as of May 20, according to data from Grant Watch. While the exact numbers remain fluid due to inconsistent reporting by federal agencies, the toll is undeniable: R01 research grants—a cornerstone of basic research—have been particularly hard-hit, with 322 grants worth nearly $790 million terminated. "The fallout from NIH funding changes is cascading through the research ecosystem," said Tanya Samazan, Editor-In-Chief. "Our survey shows just how deeply this uncertainty is affecting labs—from basic research to clinical trial infrastructure." Survey Highlights: Budget Cuts Across the Board Conducted by the Science Advisory Board (SAB) between mid- and late May, the survey collected 117 responses from U.S.-based labs, with 88 indicating their labs were impacted by NIH-related funding disruptions. Key findings include: 59% of labs report direct impacts from NIH-related grant or contract terminations, delays, or reductions. 47% report indirect impacts. Among affected labs, nearly 60% have reduced 2025 operating budgets by more than 10%. 51% report capital budget reductions exceeding 10%. When excluding labs that were uncertain or unaffected, the scale becomes even more dramatic: 71% of labs report operating budget cuts of over 10%. 71% report similar reductions in capital budgets. Lab Tools and Consumables Hit Hardest Every category of lab spending has been affected, according to survey data: 80% of labs have reduced their 2025 consumables budgets, making it the most impacted category. 63% have cut software/informatics budgets. 70% have reduced spending on devices under $50,000. Even high-end instrumentation (>$150,000) hasn't been spared, with 62% of labs trimming these budgets. Institutes Most Affected The survey findings align with NIH grant termination data indicating the hardest-hit institutions include: National Institute of Mental Health, with over $400 million in losses. National Institute of General Medical Sciences, which lost the highest number of grants (134). Institutes heavily reliant on lab instruments, including the National Institute of Biomedical Imaging and Bioengineering and the National Human Genome Research Institute. Medical schools and hospitals have borne a significant share of the burden, accounting for 50% of terminated grants and 55% of total terminated NIH dollars. A Shifting Landscape with No Clear Path Forward The rapidly evolving nature of NIH decisions—including ongoing terminations and reinstatements—has created a volatile funding environment. Labs are being forced to make difficult decisions with limited visibility into future funding. About Instrument Business Outlook (IBO)IBO is a leading newsletter providing market intelligence for the analytical instrument industry. Published by Strategic Directions International (SDi), a division of Science and Medicine Group, IBO offers in-depth coverage of technology, business, and market trends affecting the life sciences and lab tools sectors. View original content to download multimedia: SOURCE Instrument Business Outlook
